Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: HIV, Diastolic Dysfunction, Myocardial Fibrosis
Interventions: Cardiac MRI/MRS; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease
Interventions: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List; Behavioral
Lead sponsor: Ira Winer; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cerebral Palsy
Interventions: Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in lab, Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in home; Combination Product
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Months to 18 Months
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Anxiety, Burn Out
Interventions: Random assigned paradigm viewing order; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Physical Activity
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Childhood Obesity
Interventions: Family groups; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 566 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 11
States / cities: Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more

Conditions: Quality of Life
Interventions: Line Dance Class; Other
Lead sponsor: Patrick Corbin; Other
Eligibility: 50 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: IgG4-related Disease
Interventions: Abatacept; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnancy
Interventions: C31G, nonoxynol-9 (N-9); Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1,565 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 15
States / cities: Berkeley, California • Los Angeles, California • Aurora, Colorado + 11 more

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Breast PET; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions: encorafenib, Binimetinib, Cetuximab; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New York, New York • Germantown, Tennessee

Conditions: Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Interventions: SBR759, Sevelamer HCl; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • La Mesa, California • Whittier, California + 16 more

Conditions: Diabetes Mellitus, Diabetic Nephropathy
Interventions: Pirfenidone; Drug
Lead sponsor: Sharma, Kumar, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 3
States / cities: Bethesda, Maryland • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Adult Male Hypogonadism
Interventions: Testosterone Gel (FE 999093); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 16
States / cities: Huntsville, Alabama • Newport Beach, California • San Diego, California + 13 more

Conditions: Hereditary Angioedema (HAE)
Interventions: CINRYZE 500, CINRYZE 1000; Biological
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon

Conditions: Subcutaneous Fat
Interventions: CBL-514 injection, CBL-A1 Injection, CBL-A2 Injection, 0.9% Sodium Chloride; Drug
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Schizophrenia
Interventions: Asenapine 10 mg daily in the evening, Asenapine 5 mg twice daily; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Butner, North Carolina

Conditions: Plaque Psoriasis
Interventions: clobetasol propionate spray, clobetasol propionate ointment; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Fremont, California • Vallejo, California • Detroit, Michigan + 3 more

Conditions: Non-Small Cell Lung Carcinoma, Compliance Behavior, Prevention Harmful Effects
Interventions: Patient Navigation; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 55 Years to 74 Years
Enrollment: 447 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Duarte, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615;RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more

Conditions: Wrinkle, Pigmentation, Skin Laxity, Skin Scarring
Interventions: Treatment with BTL-785F; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Greenwood Village, Colorado • Chevy Chase, Maryland • Birmingham, Michigan

Search by objective public record fields.

Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects

ASk Questions in GYnecologic Oncology (ASQ-GYO)

Extending taVNS Paired With Infant CIMT Into a Home-Based Setting

A Study to Assess Virtual Reality by Healthcare Providers: A Pilot Study

Validation of Objective Measures of Place-Based Physical Activity

Starting Early Obesity Prevention Program

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

University of Southern California Choreographic Institute Line Dance Study

Safety and Efficacy of Abatacept in IgG4-Related Disease

Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

Diuretics and Volume Overload in Early CKD

Comparison of Positron Emission Mammography and Contrast-enhanced Breast MRI

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes

A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Once-Daily Asenapine for Schizophrenia

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Device for Improving Skin Quality and Texture on the Face and Neck